No trading action is warranted based on this filing. The amendment is purely administrative and does not reflect any change in the company's financial condition or operations. Traders should await the next substantive filing for material updates.
Price Chart
Executive Summary
Serina Therapeutics, Inc. filed an amended 10-K/A solely to correct an incorrect version of the auditor's consent (Exhibit 23.1) from Frazier & Deeter, LLC. The amendment includes updated certifications from the CEO and CFO but contains no changes to financial statements, disclosures, or operational information from the original filing.
Key Facts
- The 10-K/A is an amendment to correct an erroneous auditor consent (Exhibit 23.1) in the original filing.
- The corrected Exhibit 23.1 provides consent for incorporation by reference of the auditor's report on financial statements for 2025 and 2024.
- New certifications from the CEO and CFO under Section 302 and 906 of Sarbanes-Oxley are included as required.
- No changes were made to financial data, disclosures, or other exhibits beyond the auditor consent and certifications.
- The company confirms it is not a shell company and has filed all required reports.
Financial Impact
No financial impact — this is a procedural correction with no changes to financial statements or guidance.
Risk Factors
- The repeated need for an amendment could signal internal control or filing process weaknesses, though not material to financial reporting.
- Low trading volume and market cap ($28M) may amplify volatility on any future news, but this filing is not a catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001708599-26-000022 |
| Document: ser-10kxa20251231xexx311.htm | 0001708599-26-000022 |
| Document: ser-xaserx20251231xexx312.htm | 0001708599-26-000022 |
| Document: ser-10kxaserx20251231xexx32.htm | 0001708599-26-000022 |
| Document: ser-10kxfdconsentx20260326.htm | 0001708599-26-000022 |
| Document: 0001708599-26-000022-index-headers.html | 0001708599-26-000022 |
| Document: 0001708599-26-000022-index.html | 0001708599-26-000022 |
| Document: 0001708599-26-000022.txt | 0001708599-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $2.57 $2.16 | ▼ −15.95% | ▼ −14.86% | $1.71 (−33.46%) |
Jul 23, 2026 13w ago | Press Release | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.71 (−18.18%) |
Jul 22, 2026 13w ago | 8-K | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.71 (−18.18%) |
Jun 4, 2026 20w ago | EFFECT | $1.86 $1.81 | ▲ +2.69% | ▲ +0.14% | $1.71 (+8.06%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▼ −0.56% | ▼ −1.02% | $1.71 (−5.00%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▲ +0.56% | ▲ +1.02% | $1.71 (+5.00%) |
May 22, 2026 22w ago | S-3 | $1.92 $1.81 | ▲ +5.73% | ▲ +6.81% | $1.71 (+10.94%) |
Mar 27, 2026 30w ago | 10-K/A | $2.27 $2.15 | ▼ −5.29% | ▼ −9.15% | $1.71 (−24.67%) |
Mar 25, 2026 30w ago | Press Release | $2.61 $2.12 | ▼ −18.77% | ▼ −20.41% | $1.71 (−34.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers